Resources
75 Results (showing 61 - 70)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 4/11/2023 (updated 3/27/2024)
The first phase of the campaign created by the White House Office of National Drug Control Policy (ONDCP) and Ad Council was launched to education young people on the dangers of fentanyl and the life-saving effects of Naloxone, a medicine that reverses opioid-related overdoses. This campaign expands on the Ad Council's The Real Deal on Fentanyl platform.
Posted 4/11/2023 (updated 3/27/2024)
The American Medical Association (AMA) Collective Trauma Toolkit includes 6 practical tools, actionable steps, and supporting resources to help your organization respond effectively to collective trauma.
Posted 6/13/2023 (updated 3/28/2024)
Tribal communities throughout the United States are often acknowledged as having higher rates of negative health outcomes, including higher rates of overdose and substance use, with little context given to the contributing historical and contemporary factors.
Posted 6/22/2023 (updated 3/28/2024)
The Practical Guide for Implementing a Trauma-Informed Approach was developed by SAMHSA. The guide focuses on tools and strategies for implementing a Trauma-Informed Approach across ten domains.
Posted 7/21/2023 (updated 3/28/2024)
Disparities in access to naloxone exist and organizations are working to remove some of these barriers by utilizing innovative methods such as vending machines to distribute the overdose medication. This provides life-saving medication in an accessible way to everyone, although laws vary state to state on the distribution of these tools. More information on naloxone vending machines can be found in these resources by the Bureau of Justice Assistance's (BJA) Comprehensive Opioid, Stimulant, and Substance Use Program (COSSUP) and The Network for Public Health Law.
RSV 2023 Session: Quick Response Teams: Preventing Deaths While Sharing the Hope of Recovery (Day 1)
Posted 7/26/2023 (updated 3/28/2024)
The presentation discussed the development and changes in the utilization of a Quick Response Team in an Ohio rural community.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
Posted 10/23/2023 (updated 5/24/2024)
Using data from 77 harm reduction programs in 25 US states, researchers found that 12-15% of powder methamphetamine and powder cocaine also contained fentanyl although the prevalence varied geographically. Prevalence of fentanyl in crystal methamphetamine and crack cocaine was lower. Heroin and xylazine were also found in unregulated stimulants. Xylazine reduced the ability to detect fentanyl.
Posted 10/23/2023 (updated 3/27/2024)
The 2023 RCORP-CABH Onboarding Packet includes resources, tools, and strategies to support grant-funded activities, along with information on accessing TA. We hope you find the Onboarding Packet helpful as a starting point. Our TA team is here to support you through your grant, so should you have any questions related to this document or other technical assistance needs, please do not hesitate to contact your Technical Expert Lead (TEL).
Posted 1/19/2024 (updated 3/28/2024)
The FDA announced that the manufacturer of NARCAN 4 mg Nasal Spray products, Emergent BioSolutions, has extended the shelf-life of their product from 3 years to 4 years. This new extension of shelf-life was requested by the FDA to help prevent overdoses and reduce overdose-related deaths.